Advanced Solid Tumor Clinical Trials in New York, New York

45 studies are recruiting for advanced solid tumor in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

   The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Locations

   5 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07166601 on ClinicalTrials.gov

2. FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers

   The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07638371 on ClinicalTrials.gov

3. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

4. Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1004, Memorial Sloan Kettering Cancer Institute, New York, New York

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

5. A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

   This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   15 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05765851 on ClinicalTrials.gov

6. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Hospital, New York, New York

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

8. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of c…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nyu Langone Health, New York, New York

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

9. GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York

   Locations

   13 in total

   Run by

   GI Innovation, Inc.

   See if you can join NCT04977453 on ClinicalTrials.gov

10. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

    This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York

    Locations

    27 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT05898399 on ClinicalTrials.gov

11. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

    This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine Mt Sinai, New York, New York

    Locations

    61 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT05875168 on ClinicalTrials.gov

12. A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

    This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The inves…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Clinical Trial Site, New York, New York

    Locations

    4 in total

    Run by

    Arvinas Inc.

    See if you can join NCT07749586 on ClinicalTrials.gov

13. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Hospital, New York, New York

    Locations

    77 in total

    Run by

    BioNTech SE

    See if you can join NCT07070232 on ClinicalTrials.gov

14. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York

    Locations

    11 in total

    Run by

    EMD Serono Research & Development Institute, Inc.

    See if you can join NCT06641908 on ClinicalTrials.gov

15. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    21 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06997029 on ClinicalTrials.gov

16. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Memorial Sloan Kettering, New York, New York

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

17. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Avenzo Therapeutics Recruiting Site, New York, New York

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

18. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine At Mount Sinai, New York, New York

    Locations

    28 in total

    Run by

    BeOne Medicines

    See if you can join NCT05981703 on ClinicalTrials.gov

19. SLV-154 Treatment of Advanced Cancers

    This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    12 in total

    Run by

    Solve Therapeutics

    See if you can join NCT06771219 on ClinicalTrials.gov

20. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone Health Perlmutter Cancer Center, New York, New York

    Locations

    16 in total

    Run by

    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

21. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

    A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Locations

    21 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06859762 on ClinicalTrials.gov

22. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

    Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    14 in total

    Run by

    Adcendo ApS

    See if you can join NCT06597721 on ClinicalTrials.gov

23. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Medical Center, New York, New York

    Locations

    33 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov

24. Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

    ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Medical Center, New York, New York

    Locations

    3 in total

    Run by

    OncoC4, Inc.

    See if you can join NCT07408258 on ClinicalTrials.gov

25. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    David H Koch, Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov